Pin Therapeutics announced on Friday that it has signed a strategic memorandum of understanding with ImpriMed, a company specializing in artificial intelligence (AI)-powered precision medicine platforms.

The agreement is a strategic partnership to pre-validate the clinical success and differentiation of PIN-5018 in acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (HR-MDS) in real patient-derived cell lines.

PIN-5018, Pin Therapeutics' lead pipeline, is a novel molecular adhesion molecule that selectively degrades the CK1α protein. Its target indications include salivary gland cancer (adenoid cystic carcinoma, ACC), castration-resistant prostate cancer, and MSS-type colorectal cancer.

The company is currently preparing for an initial phase 1a clinical trial in these solid tumors, which aims to confirm the safety of the drug in the clinic. The company's strategic judgment will determine further expansion into AML and HR-MDS.

ImpriMed's AI platform is an AI-based analysis of cancer cells collected from patients to predict clinical response.

The collaboration will involve an ex vivo-based evaluation of drug response to PIN-5018 in AML and HR-MDS patients. Pin Therapeutics plans to obtain quantitative data to objectively predict how PIN-5018 will respond in people with AML and HR-MDS.

“Through this collaboration, we will be able to demonstrate the therapeutic potential of PIN-5018 in patients with objective data, laying a strong foundation for global technology export,” Pin Therapeutics CEO Jo Hyun-sun said.

ImpreMed CEO Lim Sung-won said, "We are pleased to collaborate with Pin Therapeutics with its unique TPD technology. With our proven precision medicine platform, we will do our best to predict and prove the clinical efficacy of Pin Therapeutics' innovative drugs to provide new hope for patients with incurable blood cancer."